Zytiga Forms Key Part of Cancer Strategy

1. Zytiga Forms Key Part
of Cancer Strategy

2. Zytiga Forms
Key Part of
Cancer
Strategy
Over the course of his career as a biotechnology investor, Dr.
Lindsay Rosenwald has helped to fund several groundbreaking
treatments. At Cougar Biotechnology, Inc., which Dr. Lindsay
Rosenwald co-founded, he helped to push the drug Zytiga through
two stages of clinical trials.

3. Zytiga Forms
Key Part of
Cancer
Strategy
Cougar Biotechnology was bought out by Johnson & Johnson while
Zytiga was still under development. The drug is now an important
part of the company’s strategy in cancer therapeutics. Zytiga , which
is approved to treat chemotherapy-naïve metastatic-castrationresistant prostate cancer and chemo-refractory metastaticcastration-resistant prostate cancer, accounts for nearly one-third of
the market for drugs of its type in the United States.

4. Zytiga Forms
Key Part of
Cancer
Strategy
The need for drugs like Zytiga is growing, as well. Prostate cancer
accounted for 14 percent of cancer diagnosed in men worldwide in
2008. The disease is primarily diagnosed in developed countries
where Johnson & Johnson has experience in operating. Overall,
cancer diagnoses are expected to grow significantly in the next
several decades.